Gingivitis, the most common form of periodontal disease, affects nearly every individual at some stage of life. Chlorhexidine is widely used as the gold standard for its treatment; however, its potential cytotoxicity and irritant effects at higher concentrations necessitate the development of safer alternatives. This study investigates the in-silico docking potential of 2,4-di-tert-butylphenol (2,4-DTBP), a phenolic compound, against four key oral pathogens associated with gingivitis—Streptococcus mutans, Aggregatibacter actinomycetemcomitans, Fusobacterium nucleatum and Porphyromonas gingivalis. Two proteins involved in virulence and biofilm formation were selected from each species. Docking analysis with Autodock was done, which revealed, 2,4-DTBP displays binding affinities comparable to chlorhexidine. Furthermore, its absorption, distribution, metabolism, excretion and toxicity profile and drug-likeness were evaluated using Swiss Absorption, Distribution, Metabolism, Excretion, Protox, Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures and Molsoft tools, indicating acceptable pharmacokinetic properties with mild irritability. In addition, minimum inhibitory concentration evaluation demonstrated that both 2,4-DTBP and chlorhexidine exhibited measurable antibacterial activity, with 2,4- DTBP showing comparatively stronger inhibition, further supporting the in-silico findings. To improve therapeutic efficacy and minimize toxicity, the compound holds strong potential for delivery through advanced systems such as nanoparticles, nanoemulsions, liposomes, phytosomes and solid lipid nanoparticles, especially when encapsulated with biocompatible polymers. These platforms can enhance stability, targeted delivery and sustained release. Therefore, 2,4-DTBP can be considered a preliminary candidate for further development in gingivitis management, particularly within biocompatible, controlled-release delivery systems.
Venugopal A, Sathyamoorthy S, Renitta E, Sathyamurthy D, Keshri V, Shankaranarayana VK, Sevanan M. Comparative in-silico docking, pharmacokinetic characterization and antimicrobial evaluation of 2,4-DTBP and chlorhexidine against gingivitis-associated oral pathogens. J Appl Pharm Sci. 2026. Article in Press. http://doi.org/10.7324/JAPS.2026.272831
1. Liu X, Xu J, Li S, Wang X, Liu J, Li X. The prevalence of gingivitis and related risk factors in school children aged 6–12 years old. BMC Oral Health. 2022;22(1):623. doi: https://doi.org/10.1186/s12903-022-02670-9
2. Sedghi LM, Bacino M, Kapila YL. Periodontal disease: the good, the bad and the unknown. Front Cell Infect Microbiol. 2021;11:766944. doi: https://doi.org/10.3389/fcimb.2021.766944
3. Koneru S, Reddy M, Jyothi VS. Evaluation and comparison of plaque detection with novel fluorescent plaque detector and disclosing agent: a clinical study. Int J Health Sci Res. 2024;14(2): 20240201. doi: https://doi.org/10.52403/ijhsr.20240201
4. Forshaw R. Dental calculus – oral health, forensic studies and archaeology: a review. Br Dent J.2022;233(11):961–7. doi: https://doi.org/10.1038/s41415-022-5266-7
5. Martínez-García M, Hernández-Lemus E. Periodontal inflammation and systemic diseases: an overview. Front Physiol. 2021;12:709438. doi: https://doi.org/10.3389/fphys.2021.709438
6. Eremenko M, Jablonowski L, Fanghänel J.Gingivitis and periodontitis. In: Schmidt E, editor. Diseases of the oral mucosa. Cham, Switzerland: Springer; 2021. doi: https://doi.org/10.1007/978-3-030-82804-2_41
7. Anwar MA, Sayed GA, Hal DM, Halder S, Alshehri AA, Al-Zharani M, et al. Herbal remedies for oral and dental health: a comprehensive review. Inflammopharmacology. 2025;33:1085–160. doi: https://doi.org/10.1007/s10787-024-01631-8
8. Ezike TC, Okpala US, Onoja UL, Nwike CP, Ezeako EC, Okpara OJ, et al. Advances in drug delivery systems, challenges and future directions. Heliyon. 2023;9(6):e17488. doi: https://doi.org/10.1016/j.heliyon.2023.e17488010
9. Kavisri M, Malathy BR, Lavanya G, Deepika P, Kamaraj C, Nicoletti M, et al. Molecular structure and bioactivities of 2,4-di-tert-butylphenol extracted from Plumbago zeylanica. Biomass Convers Biorefinery. 2024;14:23793–803. doi: https://doi.org/10.1007/s13399-023-04514-0
10. Viszwapriya D, Prithika U, Deebika S, Balamurugan K, Pandian SK. In vitro and in vivo antibiofilm potential of 2,4-di-tert-butylphenol. Microbiol Res. 2016;191:19–31. doi: https://doi.org/10.1016/j.micres.2016.05.010
11. Zhao F, Wang P, Lucardi RD, Su Z, Li S. Natural sources and bioactivities of 2,4-di-tert-butylphenol. Toxins. 2020;12(1):35. doi: https://doi.org/10.3390/toxins12010035
12. Poppolo Deus F, Ouanounou A. Chlorhexidine in dentistry: pharmacology, uses, and adverse effects. Int Dental J.2022;72(3):269– 77. doi: https://doi.org/10.1016/j.identj.2022.01.005
13. Bescos R, Du Toit L, Redondo-Rio A, Warburton PJ, Nicholas TL, Kiernan M, et al. The comparative effect of propolis and chlorhexidine mouthwash on oral nitrite-producing bacteria and blood pressure regulation. J Oral Microbiol. 2024;17(1):2439636. doi: https://doi.org/10.1080/20002297.2024.2439636
14. RVR, Jayasree DV, Biju PG, Baby S. Anti-inflammatory and anticancer activities of erythrodiol-3-acetate. Nat Prod Res. 2018;26:1–4. doi: https://doi.org/10.1080/14786419.2018.15314 06
15. Dani S, Prabhu A, Chaitra KR, Desai NC, Patil SR, Rajeev R. Assessment of Streptococcus mutans in healthy vs gingivitis and chronic periodontitis. Contemp Clin Dent. 2016;7(4):529–34. doi: https://doi.org/10.4103/0976-237X.194114
16. Xiao H, Li Y. From teeth to body: the complex role of Streptococcus mutans in systemic diseases. Mol Oral Microbiol. 2025;40(2):65–81. doi: https://doi.org/10.1111/omi.12491
17. Chen Y, Huang Z, Tang Z, Huang Y, Huang M, Liu H, et al. More than just a periodontal pathogen: Fusobacterium nucleatum. Front Cell Infect Microbiol. 2022;12:815318. doi: https://doi.org/10.3389/fcimb.2022.815318
18. Cardenas Torres SM, Quintanilla Rodriguez LE, Elizondo Elizondo. Aggregatibacter actinomycetemcomitans: a scoping review. Int J Appl Dent Sci. 2023;9(4 Pt E):308–12. doi: https://doi.org/10.22271/oral.2023.v9.i4e.1886
19. Li C, Yu R, Ding Y. Association between Porphyromonas gingivalis and systemic diseases: focus on T cells. Front Cell Infect Microbiol. 2022;12:1026457. doi: https://doi.org/10.3389/fcimb.2022.1026457
20. Sarkar A, Concilio S, Sessa L, Marrafino F, Piotto S. Modified AutoDock Vina algorithms for molecular docking. Results Chem. 2024;7:101319. doi: https://doi.org/10.1016/j.rechem.2024.101319
21. Poppolo Deus F, Ouanounou A. Chlorhexidine in dentistry: pharmacology and adverse effects. Int Dent J.2022;72(3):269–77. doi: https://doi.org/10.1016/j.identj.2022.01.005
22. Ullah NN, Hasnain SZU, Baloch R, Amin A, Nasibova A, Selakovic D, et al. Essential oil-based bio-composites for oral biofilm inhibition. Front Chem. 2024;12:1383620. doi: https://doi.org/10.3389/fchem.2024.1383620
23. Chau CHM, Giang NTT, Chau LTM, Ha NX, Thuy PT. Docking and dynamics of Prinsepia utilis phytochemicals. Inflammopharmacology. 2024;32(4): doi: https://doi.org/10.1177/17475198241305879
24. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605–2. doi: https://doi.org/10.1002/jcc.20084
25. Silva DR, Deps TD, Sakaguchi OA, de Cassia Orlandi Sardi J.Docking of phytochemicals against Streptococcus mutans. In: Dentistry. London, United Kingdom: IntechOpen; 2021. doi: https://doi.org/10.5772/intechopen.79903
26. Nithianantham S, Xu M, Yamada M, Ikegami A, Shoham M, Han YW. Crystal structure of FadA adhesin from Fusobacterium nucleatum. J Biol Chem. 2009;284(6):3865–72. doi: https://doi.org/10.1074/jbc.M805503200
27. Marongiu GL, Fink U, Schöpf F, Oder A, von Kries JP, Roderer D. Immune cell binding of Fusobacterium nucleatum via CbpF. Proc Natl Acad Sci U S A. 2025;122(15):e2418155122. doi: https://doi.org/10.1073/pnas.2418155122
28. Kaplan JB, Sukhishvili SA, Sailer M, Kridin K, Ramasubbu N. Aggregatibacter actinomycetemcomitans dispersin B: the quintessential antibiofilm enzyme. Pathogens. 2024;13(8):668. doi: https://doi.org/10.3390/pathogens13080668
29. Raj LS, MJ, JI, K, Krishna PS, KA S. Molecular docking study for inhibitors of Aggregatibacter actinomycetemcomitans toxins in treatment of aggressive periodontitis. J Clin Diagn Res. 2014;8(11):ZC48–51. doi: https://doi.org/10.7860/JCDR/2014/10067.5133
30. Wu D, Liu X, Li X, Hao L, Zhao G. Discovery of specific inhibitors of Porphyromonas gingivalis gingipains from food-derived flavonoids. Food Biosci. 2024;61:104596. doi: https://doi.org/10.1016/j.fbio.2024.104596
31. Yadalam PK, Rengaraj S, Mugri MH, Almas K, Sayed ME, Jain S, et al. Designing an immunoinformatic vaccine for peri-implantitis. Saudi J Biol Sci. 2022;29(1):622–9. doi: https://doi.org/10.1016/j.sjbs.2021.09.041
32. Hanwell MD, Curtis DE, Lonie DC, Vandermeersch T, Zurek E, Hutchison GR. Avogadro: an advanced semantic chemical editor, visualization and analysis platform. J Cheminform. 2012;4:17. doi: https://doi.org/10.1186/1758-2946-4-17
33. AbdulRazzaq M, Majeed M, Alharbi S, Al-Mohaimeed AM, Al-Juraifani AA, Mohammed Saleem S. Characterization of bioactive metabolites from Ochrosia elliptica Labill. via machine learning. RSC Adv. 2025;15(3):1251–63. doi: https://doi.org/10.1039/D5RA00021
34. O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: an open chemical toolbox. J Cheminform. 2011;3:33. doi: https://doi.org/10.1186/1758-2946-3-33
35. Jendele L, Krivak R, Skoda P, Novotny M, Hoksza D. PrankWeb: a web server for ligand binding site prediction and visualization. Nucleic Acids Res. 2019;47(1):W345–9. doi: https://doi.org/10.1093/nar/gkz424
36. Tian W, Chen C, Lei X, Zhao J, Liang J.CASTp 3.0: computed atlas of surface topography of proteins. Nucleic Acids Res. 2018;46(W1):W363–367. doi: https://doi.org/10.1093/nar/gky473
37. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16):2785–91. doi: https://doi.org/10.1002/jcc.21256
38. Fährrolfes R, Bietz S, Flachsenberg F, Meyder A, Nittinger E, Otto T, et al. ProteinsPlus: a web portal for structure analysis of macromolecules. Nucleic Acids Res. 2017;45(1):W337–343. doi: https://doi.org/10.1093/nar/gkx333
39. Abagyan R, Totrov M. Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins. J Mol Biol. 1994;235(3):983–1002. doi: https://doi.org/10.1006/jmbi.1994.1052
40. Diedrich K, Krause B, Berg O, Rarey M. PoseEdit: enhanced ligand binding communication. J Comput Aided Mol Des. 2023;37:491– 503. doi: https://doi.org/10.1007/s10822-023-00522-4
41. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717. doi: https://doi.org/10.1038/srep42717.
42. En-Nahli F, Hajji H, Ouabane M, Ghamchi M, Elhallaoui M. ADMET profiling of pyrazoles as antimicrobials. Arab J Chem. 2023;16(11):105262. doi: https://doi.org/10.1016/j.arabjc.2023.105262
43. Pires DEV, Blundell TL, Ascher DB. PkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem. 2015;58(9):4066–72. doi: https://doi.org/10.1021/acs.jmedchem.5b00104
44. Banerjee P, Eckert AO, Schrey AK, Preissner R. ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res. 2018;46(W1):W257–263. doi: https://doi.org/10.1093/nar/gky318
45. Dinu S, Matichescu A, Buzatu R, Popovici R, Dinu DC, Bratu DC, et al. Safety screening of chlorhexidine digluconate. Dent J (Basel). 2024;12(7):221. doi: https://doi.org/10.3390/dj12070221
46. De Souza LB, De Aquino SG, De Souza PP, Hebling J, Costa CA. Cytotoxicity of different chlorhexidine concentrations. Am J Dent. 2007;20(6):400–4.
47. Li YC, Kuan YH, Lee SS, Huang FM, Chang YC. Cytotoxic and genotoxic effects of chlorhexidine on macrophages. Environ Toxicol. 2014;29(4):452–8. doi: https://doi.org/10.1002/tox.21771
48. Lee TH, Hu CC, Lee SS, Chou MY, Chang YC. Chlorhexidine cytotoxicity and glutathione levels. Int Endod J.2010;43(5):430–5. doi: https://doi.org/10.1111/j.1365-2591.2010.01700.x
49. Seenivasana A, Manikkam R, Kaaria M, Balagurunathan R. Antibacterial and anticancer properties of 2,4-DTBP from streptomyces. J King Saud Univ Sci. 2022;34:102088. doi: https://doi.org/10.1016/j.jksus.2022.102088
50. Zhang J, Wang Y, Liu Z, Ali M. Exposure to environmental levels of 2,4-di-tert-butylphenol affects digestive glands and induces inflammation in Asian clam (Corbicula fluminea). Environ Toxicol. 2024;39(5):e11631346. doi: https://doi.org/10.1002/tox.24151
51. Aravinth A, Perumal P, Rajaram R. 2,4-DTBP from Dictyota ciliolata: antioxidant and anticancer activity. Biocatal Agric Biotechnol. 2023;49:102933. doi: https://doi.org/10.1016/j.bcab.2023.102933
52. da Silva ACB, Stipp RN, Mattos-Graner RO, Sampaio FC, de Araújo DAM. Influence of sub-lethal and lethal concentrations of chlorhexidine on morphology and glucosyltransferase genes expression in Streptococcus mutans UA159. Adv Microbiol. 2014;4(13):891–903. doi: https://doi.org/10.4236/aim.2014.413105
53. Kadkhoda Z, Amarlu Z, Eshraghi S, Samiei N. Antimicrobial effect of chlorhexidine on Aggregatibacter actinomycetemcomitans biofilms associated with peri-implantitis. J Dent Res Dent Clin Dent Prospects. 2016;10(3):176–80. doi: https://doi.org/10.15171/joddd.2016.028
54. Seenivasan A, Manikkam R, Kaari M, Sahu AK, Said M, Dastager SG. 2,4-Di-tert-butylphenol (2,4-DTBP) purified from Streptomyces sp. KCA1 from Phyllanthus niruri: isolation, characterization, antibacterial and anticancer properties. J King Saud Univ Sci. 2022;2:102088. https://doi.org/10.1016/j.jksus.2022.102088
Year
Month